Richard bas been Thelial’s CSO since incorporation and has been central to all business development and negotiation with clients and investors and is a principal inventor on all Thelial IP. Since summer 2016 he is CEO of Thelial.
Richard is a biomedical scientist by training, completing his Ph.D. research at the Imperial Cancer Research Fund, London. Following post-doctoral work at Harvard University and King ́s College London he moved to the biotechnology industry, first as a research group leader and then as co-founder of Thelial. He is author of more than 15 peer reviewed publications and co-inventor on two granted patents and more than 10 applications.